Skip to content

Nasdaq · CIK 0001861123

EIKN Eikon Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing 35 d ago. Close $7.47 on Oct 9, 2026, +2% from the 52-week low and -54% from the high.

Eikon Therapeutics, Inc. (EIKN) has 14 SEC Form 4 filings on file from 10 insiders, the latest filed on Sep 8, 2026. In the last 90 days insiders made 1 open-market buy worth $1.0M and 0 open-market sells worth $0, net +$1.0M.

6 open-market trades have been scored at EIKN. The newest: Column Group IV GP, LP (10% owner) bought $1.0M of stock on Sep 3, 2026, filed Sep 8, 2026, scored 40 (moderate). The largest of the 6 shown: Column Group IV GP, LP (10% owner) bought $38M on Feb 6, 2026, scored 67 (notable). 4 insiders bought within 14 days of each other around Feb 6, 2026.

EIKN closed at $7.47 on Oct 9, 2026, 2% above its 52-week low and 54% below its 52-week high.

Last 90 days

Net insider value
+$1.0M
more bought than sold
Buys
1
$1.0M by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company

Price and insider trades, last year

EIKNOct 9, 2026 · close 7.47

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Eikon Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
40ModerateColumn Group IV GP, LP
owner
buy
$1.0M
89,200 shares
--
67NotableColumn Group IV GP, LP
owner
buy
$38M
2,117,760 shares
+74%0% from low-3% from high
47ModerateForesite Capital Management IV, LLC
owner
buy
$1000k
55,555 shares
+4%-
63NotableJosh Wolfe
director, owner
buy
$5.0M
277,776 shares
--
63NotableJosh Wolfe
director, owner
buy
$5.0M
277,776 shares
--
63NotableKenneth C Frazier
director
buy
$2.0M
111,111 shares
--

Transactions

The newest 50 of 88 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 3, 2026Column Group IV GP, LP
owner
POpen-market purchase
Common Stockindirect: See footnote
+89,200$11.56$1.0M89,20035 d ago
Mar 2, 2026Roy D. Baynes
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+134,088$0.00$0134,088Mar 4, 2026
Mar 2, 2026Kenneth C Frazier
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,873$0.00$025,873Mar 4, 2026
Mar 2, 2026Michael A Klobuchar
Chief Operating Officer
AGrant or award
Stock Option (Right to Buy)derivative
+87,157$0.00$087,157Mar 4, 2026
Mar 2, 2026Robert Luther Huffines
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,873$0.00$025,873Mar 4, 2026
Mar 2, 2026Benjamin Bruno Thorner
See Remarks
AGrant or award
Stock Option (Right to Buy)derivative
+67,044$0.00$067,044Mar 4, 2026
Mar 2, 2026Alfred Lloyd Bowie Jr.
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+67,044$0.00$067,044Mar 4, 2026
Mar 2, 2026Roger M Perlmutter
See remarks
AGrant or award
Stock Option (Right to Buy)derivative
+268,176$0.00$0268,176Mar 4, 2026
Feb 6, 2026Roger M Perlmutter
See remarks
CConversion
Common Stockindirect: See Footnote
+284,857--284,857Feb 10, 2026
Feb 6, 2026Roger M Perlmutter
See remarks
CConversion
Series A-1 Preferred Stockderivativeindirect: See Footnote
-1,268,891--0Feb 10, 2026
Feb 6, 2026Roger M Perlmutter
See remarks
CConversion
Series D Preferred Stockderivativeindirect: See Footnote
-855,512--0Feb 10, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group IV, LP
+1,296,629--1,360,320Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group IV, LP
+1,403,568--2,763,888Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group IV, LP
+110,928--2,874,816Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group IV-A, LP
+44,249--47,601Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group IV-A, LP
+47,898--95,499Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group IV-A, LP
+3,785--99,284Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Common Stockindirect: By The Column Group Opportunity III, LP
+688,283--688,283Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
POpen-market purchase
Common Stockindirect: By The Column Group IV, LP
+1,437,323$18.00$26M4,312,139Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
POpen-market purchase
Common Stockindirect: By The Column Group IV-A, LP
+49,556$18.00$892k148,840Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
POpen-market purchase
Common Stockindirect: By The Column Group Opportunity III, LP
+630,881$18.00$11M1,319,164Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series A Preferred Stockderivativeindirect: By The Column Group IV, LP
-9,670,000--0Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series A Preferred Stockderivativeindirect: By The Column Group IV-A, LP
-330,000--0Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series A-1 Preferred Stockderivativeindirect: By The Column Group IV, LP
-10,467,526--0Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series A-1 Preferred Stockderivativeindirect: By The Column Group IV-A, LP
-357,216--0Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series C-1 Preferred Stockderivativeindirect: By The Column Group IV, LP
-827,278--0Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series C-1 Preferred Stockderivativeindirect: By The Column Group IV-A, LP
-28,229--0Feb 9, 2026
Feb 6, 2026Column Group IV GP, LP
owner
CConversion
Series D Preferred Stockderivativeindirect: By The Column Group Opportunity III, LP
-5,133,076--0Feb 9, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+1,340,878$0.00$01,340,878Feb 6, 2026
Feb 4, 2026Josh Wolfe
director, owner
POpen-market purchase
Common Stockindirect: See footnote
+138,888$18.00$2.5M138,888Feb 6, 2026
Feb 4, 2026Kenneth C Frazier
director
POpen-market purchase
Common Stock
+111,111$18.00$2.0M111,111Feb 6, 2026
Feb 4, 2026Josh Wolfe
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+138,888$18.00$2.5M138,888Feb 6, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+335,521$0.00$01,676,399Feb 6, 2026
Feb 4, 2026Josh Wolfe
director, owner
POpen-market purchase
Common Stockindirect: See footnote
+138,888$18.00$2.5M138,888Feb 6, 2026
Feb 4, 2026Josh Wolfe
director, owner
POpen-market purchase
Common Stockindirect: See Footnote
+138,888$18.00$2.5M138,888Feb 6, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+37,855$0.00$01,714,254Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Common Stockindirect: See footnote
+2,387,705--2,387,705Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Common Stockindirect: See Footnote
+2,387,705--2,387,705Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Common Stockindirect: See Footnote
+1,151,540--1,290,428Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Common Stockindirect: See footnote
+1,151,540--1,290,428Feb 6, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+229,428$0.00$01,943,682Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Common Stockindirect: See footnote
+2,155,765--2,294,653Feb 6, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+697,885$0.00$0697,885Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Common Stockindirect: See Footnote
+2,155,765--2,294,653Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Series A Preferred Stockderivativeindirect: See footnote
-10,000,000--0Feb 6, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+37,855$0.00$0735,740Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Series A Preferred Stockderivativeindirect: See Footnote
-10,000,000--0Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Series A-1 Preferred Stockderivativeindirect: See footnote
-7,807,026--0Feb 6, 2026
Feb 4, 2026Foresite Capital Management IV, LLC
owner
CConversion
Common Stockindirect: See Footnote
+1,626$0.00$0737,366Feb 6, 2026
Feb 6, 2026Josh Wolfe
director, owner
CConversion
Series A-1 Preferred Stockderivativeindirect: See Footnote
-7,807,026--0Feb 6, 2026
50 of 88 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about EIKN

Answered from the filings on this page, as of the latest one.

Are insiders buying EIKN?

As of Sep 8, 2026, SEC Form 4 filings show 1 open-market buy worth $1.0M by 1 insider and 0 open-market sells worth $0 by 0 insiders at Eikon Therapeutics, Inc. in the last 90 days, net +$1.0M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.

Who was the last insider to trade EIKN on the open market?

Column Group IV GP, LP (10% owner) bought $1.0M of EIKN on Sep 3, 2026 and filed the Form 4 on Sep 8, 2026. InsiderTell scored 40 (moderate).

How many insiders file Form 4 at Eikon Therapeutics, Inc.?

10 people have filed a Form 4 at Eikon Therapeutics, Inc., among them Roy D. Baynes (Chief Medical Officer), Alfred Lloyd Bowie Jr. (Chief Financial Officer), Column Group IV GP, LP (10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

EIKN insider trading: Eikon Therapeutics, Inc. | InsiderTell